Sean Murphy Net Worth

The estimated Net Worth of Sean Murphy is at least $147 Thousand dollars as of 14 July 2020. Mr. Murphy owns over 10,000 units of Radius Recycling stock worth over $146,800 and over the last 8 years he sold RDUS stock worth over $0. In addition, he makes $0 as Director at Radius Recycling.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Murphy RDUS stock SEC Form 4 insiders trading

Sean has made over 1 trades of the Radius Recycling stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of RDUS stock worth $160,000 on 14 July 2020.

The largest trade he's ever made was buying 10,000 units of Radius Recycling stock on 14 July 2020 worth over $160,000. On average, Sean trades about 1,000 units every 0 days since 2016. As of 14 July 2020 he still owns at least 10,000 units of Radius Recycling stock.

You can see the complete history of Mr. Murphy stock trades at the bottom of the page.

Sean Murphy biography

Sean Murphy serves as Director of the Company. Sean has several decades of experience in the industry across pharmaceuticals, diagnostics, and global markets. Sean worked at Abbott Laboratories for 30-years where he led the corporate business development and mergers and acquisition activity. Sean is currently on the boards of Poseida Therapeutics, a publicly traded cell and gene engineering technology company and Xenex Corporation, a privately held UV based technology company focused on eradicating healthcare associated infections generated by a wide range of micro-organisms, as well as Immucor, a privately held leading blood and tissue diagnostics company. Sean has also been an industry advisor to Evercore, a boutique investment bank and in that role, advised dozens of companies with regards to strategy.

What's Sean Murphy's mailing address?

Sean's mailing address filed with the SEC is C/O RADIUS HEALTH, INC., 22 BOSTON WHARF ROAD, 7TH FLOOR, BOSTON, MA, 02210.

Insiders trading at Radius Recycling

Over the last 11 years, insiders at Radius Recycling have traded over $1,066,622 worth of Radius Recycling stock and bought 11,047,648 units worth $180,729,288 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., Growth N Vbb Biotech Ag Bio..., and Capital Management Lp Rosen.... On average, Radius Recycling executives and independent directors trade stock every 34 days with the average trade being worth of $1,552,483. The most recent stock trade was executed by Stefano R. Gaggini on 6 May 2024, trading 1,021 units of RDUS stock currently worth $18,960.

What does Radius Recycling do?

founded in 1906 as a one-man scrap metal operation, schnitzer steel industries, inc., has become one of the nation's largest recyclers of scrap metal, a leading provider of used and recycled auto parts and a manufacturer of finished steel products. with a rapidly growing national and global reach, the company achieved $2.5 billion in revenues in fiscal 2014 and was ranked #853 in the 2015 fortune 1000 list of companies. schnitzer steel common stock is traded on the nasdaq stock market under the symbol schn. with corporate headquarters based in portland, oregon, the company is split into three vertically integrated business units, the metals recycling business, the auto parts business and the steel manufacturing business. career site: http://www.schnitzersteel.com/careers.aspx

Complete history of Mr. Murphy stock trades at Novan Inc, Radius Recycling, and Poseida Therapeutics

Radius Recycling executives and stock owners

Radius Recycling executives and other stock owners filed with the SEC include:

• Charles Morris,
  Chief Medical Officer
• Chhaya Shah,
  Sr. VP & Chief Bus. Officer
• G. Kelly Martin,
  CEO, Pres & Director
• Salvador Grausso III,
  Sr. VP & Head of U.S. Patient access
• Danielle Holtschlag,
  VP of Sales & Head of U.S. Sales Channels
• Owen Hughes,
  Independent Chairman of the board
• Elhan Webb,
  Investor Relations
• Sean Murphy,
  Director
• Chhaya Shah,
  Senior Vice President - Technical Operations
• Dan Dolan,
  Principal Financial Officer, Principal Accounting Officer, Treasurer
• G. Kelly Martin,
  President, Chief Executive Officer, Director
• Peter A. Schwartzman,
  Head of Corp. Fin.
• Mark William Conley CPA,
  VP, CFO, Principal Accounting Officer & Treasurer
• Averi Price,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Ethan Holdaway,
  Head of Investor Relations
• Steven Helwig,
  Principal Fin. & Accounting Officer and Interim Treasurer
• Dr. John A. Katzenellenbogen,
  Founder & Member of the Scientific Advisory Board
• Dr. Michael Rosenblatt M.D.,
  Founder, Board Observer & Member of Scientific Advisory Board
• Dr. John Thomas Potts Jr., DSc, M.D.,
  Founder & Member of the Scientific Advisory Board
• Dr. Stavros C. Manolagas,
  Founder & Member of the Scientific Advisory Board
• Growth N Vbb Biotech Ag Bio...,
  
• Lorraine A. Fitzpatrick,
  Chief Medical Officer
• Alan H Auerbach,
  Director
• Bio Ventures Iv Llc Scopa J...,
  
• Ansbert Gadicke,
  Director
• Robert Ward,
  President & Chief Exec Officer
• Gregory C. Williams,
  Chief Development Officer
• Debasish Roychowdhury,
  Director
• Brent Hatzis Schoch,
  Sr. VP, General Counsel
• Kurt Graves,
  Director
• Cathy Friedman,
  Director
• Willard H Dere,
  Director
• Bioventures Iii Llchenner D...,
  
• Luke Evnin,
  10% owner
• Dinesh Purandare,
  SVP,Global Oncology/Commercial
• David P. Snow,
  Chief Commercial Officer
• Jose Carmona,
  Chief Financial Officer
• Anthony Rosenberg,
  Director
• Jean Pierre Garnier,
  Director
• Nicholassimon Nicholas J Ii...,
  
• Gary Hattersley,
  Sr. VP & Chief Scientific Off.
• Brian Nicholas Harvey,
  Sr. Vice President & CFO
• Gregory R Friedman,
  
• Rhonda D Hunter,
  
• David L Jahnke,
  
• Jesper Hoeiland,
  President and CEO
• Danielle Holtschlag,
  Vice President, Sales
• Joseph Francis Kelly,
  Sr. VP of Sales and Marketing
• Jessica Hopfield,
  Director
• Glenda J Minor,
  
• Michael W Sutherlin,
  
• Bioscience Iii, L.P.F2 Bios...,
  
• Martin Muenchbach,
  Director
• Morana Jovan Embiricos,
  Director
• Bioscience Iv L.P.F2 Biosci...,
  
• Bioscience Iii, L.P.F2 Bios...,
  
• Alan G Harris,
  Executive Medical Officer
• Elizabeth Stoner,
  Director
• Bioventures Iii Llchenner D...,
  
• Bioscience Iv L.P.F2 Biosci...,
  
• Mark Durand,
  Chief Commercial Officer
• Bio Ventures Iv Llc Scopa J...,
  
• Bio Ventures Iv Llc Scopa J...,
  
• Bioventures Iii Llcmpm Biov...,
  
• Leslie L Shoemaker,
  
• Target N Vbb Biotech Ag Bio...,
  
• Machelle Sanders,
  Director
• Sal Grausso,
  Chief Commercial Officer
• James George Chopas,
  Principal Finance Accounting
• Steven Helwig,
  Principal Financial Officer
• Capital Management Lp Rosen...,
  
• Mark William Conley,
  VP, Chief Financial Officer
• Susan Vissers Lisa,
  Director
• Jennifer Jarrett,
  Director
• Elizabeth Messersmith,
  Senior Vice President
• Tamara L. Lundgren,
  Chairman, President & CEO
• James Matthew Vaughn,
  SVP, GC, CCO, Corp. Secretary
• Steven Heiskell,
  SVP & President, Recycling P&S
• Mark Schuessler,
  VP and CAO
• Brian Souza,
  SVP, Chief Ops Mgmt Officer
• Richard Peach,
  EVP, Chief Strategy Officer
• Wilson D Erich,
  SVP, Chief HR Officer
• Stefano R. Gaggini,
  SVP, CFO